Ozanezumab

Ozanezumab
Monoclonal antibody
Type	?
Source	Humanized (from mouse)
Target	Nogo-A
Clinical data
ATC code	none;
Identifiers
CAS Number	1310680-64-8;
ChemSpider	none;
UNII	123I05210W;
KEGG	D10331;
Chemical and physical data
Formula	C6446H10016N1712O2010S48
Molar mass	145195.89 g·mol−1

Ozanezumab is a monoclonal antibody designed for the treatment of ALS and multiple sclerosis.^[1]

Ozanezumab targets a protein called Neurite Outgrowth Inhibitor (NOGO-A) or Reticulon 4 (RTN4). NOGO-A is a protein that in humans is encoded by the RTN4 gene that has been identified as an inhibitor of neurite outgrowth specific to the central nervous system. NOGO-A is found at higher than normal levels in persons with ALS.

This drug was developed by GlaxoSmithKline (GSK) under the identifier GSK 1223249.

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Ozanezumab, American Medical Association.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Ozanezumab, American Medical Association.

[1]